<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981318</url>
  </required_header>
  <id_info>
    <org_study_id>Rodwick01</org_study_id>
    <nct_id>NCT00981318</nct_id>
  </id_info>
  <brief_title>Pilot Assessment of Lopinavir/Ritonavir and Maraviroc</brief_title>
  <acronym>PALM</acronym>
  <official_title>Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodwick, Barry M., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rodwick, Barry M., M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no
      nucleoside medications) in HIV patients failing their initial antiviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As long-term toxicity to many of the nucleoside medications have become known, interest has
      increased in treatment regimens that do not use these medications. This study is to assess
      the response of one such &quot;nucleoside-sparing&quot; therapy in patients who are showing failure to
      their initial nucleoside-containing treatment regimen.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to enroll expected number of subjects
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic response defined as viral load reduction of &gt;/= 1 log</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess proportion of patients with HIV-1 viral load &lt; 48 copies</measure>
    <time_frame>48 weks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess time to loss of virologic response</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess development of resistance mutations in patients who develop rebound</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare serum lipid profile changes</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess degree of immune reconstitution</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>HIV Infections</condition>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir plus maraviroc</intervention_name>
    <description>lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid</description>
    <arm_group_label>lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid</arm_group_label>
    <other_name>Kaletra</other_name>
    <other_name>lopinavir</other_name>
    <other_name>Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV viral load &gt; 1,000 on current antiviral medications

          -  No resistance to study medications

          -  Over 18 years of age

        Exclusion Criteria:

          -  Hepatitis B co-infection

          -  Pregnancy

          -  Previous therapy with either of the study medications

          -  Ongoing substance abuse

          -  Significant history of other physical disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry M. Rodwick, M. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barry M. Rodwick, M. D.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barry M. Rodwick, M. D.</name>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <zip>34695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>June 20, 2015</last_update_submitted>
  <last_update_submitted_qc>June 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rodwick, Barry M., M.D.</investigator_affiliation>
    <investigator_full_name>Barry M. Rodwick, M. D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

